Drug Combination Details
| General Information of the Combination (ID: C82598) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Athymic nude mice were injected with 5*106 HuH-7 cells subcutaneously in the right flank in 100-mL aliquots mixed with Matrigel in 1:1 ratio. | |||||
| Experimental
Result(s) |
The combination of triptolide and sorafenib was superior to either drug alone in inducing apoptosis and decreasing viability, whereas triptolide alone was sufficient to decrease nuclear factor kappaB activity. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery. 2014 Aug;156(2):270-9. | |||
